A group including corporate financier Carl Icahn held talks with an executive of
about selling the vision correction laser maker to a larger company.
According to a filing with the
Securities and Exchange Commission
, the Icahn-led group said it believes Visx would benefit from competition with better capitalized and broader-based companies in its field.
The group spoke to Visx President and Chief Operating Officer Elizabeth Davila about increasing its poison pill threshold of 10%, calling it "unreasonably low." The group said it acquired a 9.9% stake, equal to more than 6 million common shares, because it believes the shares are undervalued.
Visx adopted the poison pill in July in response to Icahn's proposal to acquire more than $15 million of the company's stock, but less than 15% of the common shares outstanding.
The filing stated that Davila would take the group's views "under advisement."
Shares of Visx closed up $2.63, or 12.9%, to $23 in
New York Stock Exchange